Lymphatic system

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives

Retrieved on: 
Thursday, January 5, 2023
Cancer, ONO, IPSC, Annual general meeting, Society, SITC, Workforce, Mab, CD20, Patient, Lymphatic system, BCMA, CXCR2, Preclinical development, Treatment, Degenerative disease, Cichocki, FDA, IND, ADR, HER2, B-cell lymphoma, Ono Pharmaceutical, Pharmacokinetics, ASH, Society for Immunotherapy of Cancer, Nature Communications, Food, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Destiny, NHL, Acute myeloid leukemia, NK, CD38, Immunotherapy, Investigational New Drug, MM, Risk, Disease, CAR, Tumor microenvironment, B cell, Multiple myeloma, Multiplexing, Vaccine, Pharmaceutical industry, Janssen, Safety

In addition, we look forward this year to the further emergence of our iPSC-derived CAR T-cell programs for the treatment of hematologic malignancies and solid tumors.

Key Points: 
  • In addition, we look forward this year to the further emergence of our iPSC-derived CAR T-cell programs for the treatment of hematologic malignancies and solid tumors.
  • Ongoing Phase 1 Study of FT576 BCMA-targeted CAR NK Cell Program to Accrue Higher-dose, Multi-dose Treatment Cohorts.
  • The Company ended the fourth quarter of 2022 with unaudited cash, cash equivalents, and receivables totaling approximately $475 million.
  • Based on its current operating plan, the Company expects to have sufficient financial resources to fund operations through 2025.

Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results

Retrieved on: 
Thursday, January 5, 2023
UHMW, OGM, DNA, Lymphatic system, Genomics, SAN, Acquisition, Overalls, Data analysis, Workflow, Doctor of Philosophy, Renewable energy, Video game

SAN DIEGO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported certain unaudited preliminary financial and commercial highlights for the fourth quarter and fiscal year ended December 31, 2022. The Company’s full results for the fourth quarter and the fiscal year ended December 31, 2022 are not yet available.

Key Points: 
  • The Company’s full results for the fourth quarter and the fiscal year ended December 31, 2022 are not yet available.
  • milestones we set out at the beginning of 2022,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.
  • “Bionano issued revenue guidance for the first time in 2022, and we not only came in at the high end of our guidance each quarter, but we exceeded our total 2022 guidance range.
  • Additional information and disclosures would be required for a more complete understanding of Bionano’s financial position and results of operations as of and for the fourth quarter and year-ended December 31, 2022.

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

Retrieved on: 
Thursday, January 5, 2023
ODD, Oncology, Society, Conjugation, Trastuzumab, Westin St. Francis, Cetuximab, American Society of Hematology, Paclitaxel, Investment, AML, Pembrolizumab, Silicon, Eli Lilly, Squamous cell carcinoma, FDA, IND, HER2, UC, Food and Drug Administration Amendments Act of 2007, MDS, Society for Immunotherapy of Cancer, Bayer, Partnership, Silicon Valley Bank, Food, Therapy, Brentuximab vedotin, CD47, SAN, Acute myeloid leukemia, Safety, Webcast, ALX, Microdeletion syndrome, Immunotherapy, Investigational New Drug, News, Platinum, Lymphatic system, Breast cancer, Patient, ADC, PD-L1, Conference, ND, Azacitidine, Fast Track, Medicine, Pharmaceutical industry, Silviculture, Management, Vaccine, HNSCC, Cancer, Portola Pharmaceuticals

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2023.
  • “2022 marked a successful year of continued clinical and corporate accomplishments for ALX Oncology.
  • Expansion of the ADC platform acquired from ScalmiBio to identify clinical development candidates by the second half of 2023.
  • ALX Oncology ended the third quarter 2022 with approximately $293.1 million in cash and cash equivalents.

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

Retrieved on: 
Thursday, January 5, 2023
Cancer, Immunotherapy, Head, TCR, Therapy, Society for Immunotherapy of Cancer, SITC, Lymphatic system, IND Crosstown Line, MBA, CPA, Growth, Patient, Hlas, PRAME, MAGE-A1, IND, HPV, Neoplasm, Pharmaceutical industry, Vaccine, Medical imaging, Finance

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced its 2023 clinical pipeline plans and highlighted recent corporate achievements.

Key Points: 
  • “We made significant progress and growth in 2022, positioning both our solid tumor and hematologic malignancies programs for important data readouts in 2023,” said David P. Southwell, President and Chief Executive Officer.
  • “Our solid cash runway funds us well into 2024, seeing us through to multiple value-generating milestones.
  • We believe that 2023 will be a pivotal year for TScan as we continue to advance our industry-leading clinical stage portfolio of TCR-T therapy candidates in both our solid tumor and hematologic malignancies programs.”
    Debora Barton, M.D., Chief Medical Officer added, “We look forward to multiple clinical milestones next year.
  • The Company expects to report initial multiplex therapy data for this program in 2024

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 4, 2023
Patient, Conference, SAN, Lymphatic system, Therapy, Pharmaceutical industry, Broadcasting

SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix’s achievements in 2022 and major goals for 2023 at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:45 pm PT.

Key Points: 
  • SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix’s achievements in 2022 and major goals for 2023 at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:45 pm PT.
  • The presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations .
  • The archived webcast will be available on the Nurix website for 30 days after the event.

Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023

Retrieved on: 
Tuesday, January 3, 2023
Epstein–Barr virus, Therapy, CFO, Optimism, Lymphatic system, Growth, Patient, Safety, Society, TT11, ASH, Pharmaceutical industry, Management, Polaris Partners

“I believe that this strategic refocus on our allogeneic platform positions the company at the forefront of CAR-T innovation during 2023 and beyond,” stated Thomas Willemsen, President and CEO of Tessa Therapeutics.

Key Points: 
  • “I believe that this strategic refocus on our allogeneic platform positions the company at the forefront of CAR-T innovation during 2023 and beyond,” stated Thomas Willemsen, President and CEO of Tessa Therapeutics.
  • During 2022, Tessa enhanced its executive management team with the appointment of Thomas Willemsen as President and CEO and Wilson W. Cheung as CFO.
  • Today, Tessa has announced that Steve Krognes will serve as the company’s new Chairman of the Board of Directors.
  • “We would like to extend our deepest gratitude to Dr. Ando for his leadership and contribution to the growth and development of Tessa.

Proactive news headlines including Blackstone Minerals, Elixir Energy, Magmatic Resources and Ioneer Ltd

Retrieved on: 
Tuesday, December 20, 2022
Elixir, Lithium, Well, Federal Register, Halls Creek, Western Australia, CRR, ASX, Lymphatic system, First Nations, SPP, BSX, Mick, KFM, TSX, CCZ, REE, T92, MAG, OTCQX, Notice of Intent to Lien, Processor register, Corvette, INR, BLM, Peak, OTC, AAJ, LSE, EXR, Sale, SHP, OTCQB, Government, PSC, TKR, NOI, Proactivity, Saskatchewan Government Insurance, Oil, Mining, Rare-earth element, Central West (New South Wales)

Click here

Key Points: 
  • Click here
    Moho Resources Ltd (ASX:MOH) has completed the first phase of reconnaissance drilling across exploration licence E74/695 at the Peak Charles Project, which it hopes to turn into a multi-commodity asset.
  • Click here
    Critical Resources Ltd (ASX:CRR) has executed a binding purchase and sale agreement with TSX-V lister Power Metals Corp to acquire its Gullwing-Tot Lakes property in Ontario, Canada.
  • Click here
    Peninsula Energy Ltd (ASX:PEN, OTCQB:PENMF) has completed its share purchase plan (SPP) to eligible shareholders and has raised a total of A$1 million.
  • Click here
    RemSense Technologies Ltd (ASX:REM) has been a awarded a virtualplant contract with a total value of $206,000.

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

Retrieved on: 
Monday, December 19, 2022
BIIB, Hoffmann-La Roche, Economics, Food, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Genentech, Lymphatic system, Mantle cell lymphoma, CD3, Patient, Biogen, Antibody, Phase, CD20, EMA, Roche, Fine chemical, Vaccine, DLBCL

Under the terms of the agreement, Biogen will have no payment obligations and will receive tiered royalties on potential net sales of glofitamab within the United States as part of the companies long-standing collaboration on antibodies targeting CD20.

Key Points: 
  • Under the terms of the agreement, Biogen will have no payment obligations and will receive tiered royalties on potential net sales of glofitamab within the United States as part of the companies long-standing collaboration on antibodies targeting CD20.
  • Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody being developed by Roche for the treatment of B-cell non-Hodgkin’s lymphomas, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and other blood cancers1.
  • If approved, glofitamab has the potential to be a first-in-class fixed-duration CD20xCD3 T-cell engaging bispecific antibody in DLBCL.
  • The companies have had a collaboration on antibodies targeting CD20 since 1995.

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Retrieved on: 
Monday, December 19, 2022
Dana–Farber Cancer Institute, Fred Hutchinson Cancer Research Center, Clinical trial, GBM, BPDCN, Cancer, Investigational New Drug, Infection, Glioblastoma, Translation, Food, SRT, Drug discovery, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, American Association for Cancer Research, MD Anderson Cancer Center, City, Birmingham, Malignancy, Leukemia, CAR, Patient, Lymphatic system, Duke University, Chronic lymphocytic leukemia, Mayo, Waldenström, Degenerative disease, Mayo Clinic, Mustang, City of Hope, Safety, Investigator, A Call for Unity, WM, University, IND, Hematological Cancer Research Investment and Education Act, Toxic epidermal necrolysis, CD20, Clinical professor, CR, Cell, Pharmaceutical industry

WORCESTER, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced recent CAR T cell therapy portfolio updates and provided anticipated milestones for 2023.

Key Points: 
  • WORCESTER, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced recent CAR T cell therapy portfolio updates and provided anticipated milestones for 2023.
  • Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “In 2022, Mustang successfully advanced our CAR T cell therapy portfolio which has laid the foundation for us to achieve multiple milestones in the coming year.
  • The combination leverages MB-108 to make cold tumors “hot,” thereby improving the efficacy of MB-101 CAR T cell therapy.
  • Additionally, Mustang plans to file an IND application for a multicenter Phase 1 clinical trial once a lead CAR construct has been identified.

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

Retrieved on: 
Friday, January 6, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Research, Genetics, Science, Clinical Trials, CMC, Food, Gene editing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NHL, Lymphatic system, CAR, Patient, Regulatory affairs, FDA, Lymphoma, Precision, Pharmaceutical industry

Azer-cel is Precision BioSciences lead allogeneic CAR T candidate being evaluated for relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) in subjects who have relapsed following autologous CAR T treatment.

Key Points: 
  • Azer-cel is Precision BioSciences lead allogeneic CAR T candidate being evaluated for relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) in subjects who have relapsed following autologous CAR T treatment.
  • “We are pleased with the FDA feedback on key components of our planned CMC package to support azer-cel ongoing development.
  • “There are currently no FDA-approved allogeneic CAR T products to address the high unmet need of the CAR T relapsed or refractory patient population.
  • An effective off-the-shelf allogeneic CAR T treatment has the potential to offer clinical benefit to this growing population of lymphoma patients.”